Treatment with ibandronate preserves bone in experimental tumour-induced bone lossA. H. A. Kurth, MD; S.-Z. Kim; and I. SedlmeyerOrthopaedic Biomechanics Laboratory, Beth Israel Deaconess Medical Centre and Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. L. Hovy, MD Orthopädische Universitätsklinik Friedrichheim, Marienburgstrasse 2, 60528 Frankfurt/Main, Germany. F. Bauss, PhD Roche Diagnostics Boehringer Mannheim GmbH, Pharma Research Bone Metabolism, Sandhofstrasse 116, D-68305 Mannheim, Germany. Correspondence should be sent to Dr A. H. A. Kurth at the Department of Orthopaedic Surgery, University Hospital, Marienburgstrasse 2, 60528 Frankfurt/Main, Germany. Cancer-induced bone diseases are often associated with increased bone resorption and pathological fractures. In recent years, osteoprotective agents such as bisphosphonates have been studied extensively and have been shown to inhibit cancer-related bone resorption in experimental and clinical studies. The third-generation bisphosphonate, ibandronate (BM 21.0955), is a potent compound for controlling tumour osteolysis and hypercalcaemia in rats bearing Walker 256 carcinosarcoma. We have studied the effect of ibandronate given as an interventional treatment on bone strength and bone loss after the onset of tumour growth in bone. Our results suggest that it is capable of preserving bone quality in rats bearing Walker 256 carcinosarcoma cells. Since other bisphosphonates have produced comparable results in man after their success in the Walker 256 animal models our findings suggest that ibandronate may be a powerful treatment for maintaining skeletal integrity in patients with metastatic bone disease. This article has been cited by other articles:
|
|
||||||||||||
